Designated SD-VG-API-P for oral and dry-blend presentations and SD-VG-API-I for low-endotoxin injectable starting material, Sini Decoction Powder Veterinary Grade API is a preservative-free, carrier-free dried decoction extract supported for formulation into tablets, injections, capsules, powders, granules, premix, and solutions. It is prepared by aqueous decoction of the three-herb formula comprising processed Aconitum carmichaelii root, Zingiber officinale rhizome, and Glycyrrhiza uralensis root, followed by concentration, filtration, and vacuum drying or spray drying. The resulting powder is controlled as a multi-constituent botanical API rather than as a simple comminuted herbal material. Because the formula contains processed aconite, the release specification includes targeted chromatographic control for diester diterpene alkaloids, marker reproducibility for liquiritin and 6-gingerol, residual moisture, total ash, and microbial burden. In formulation use, the API is differentiated from premix carriers, single-marker extracts, and fluid extracts by the absence of added excipients and by the requirement to meet veterinary pharmacopoeial assay and impurity thresholds applicable to the chosen dosage form.

What Limits Diester Aconitine Alkaloid Carryover in Veterinary Decoction Powders?

In the Sini Decoction Powder Veterinary Grade API, the processed Aconiti Radix Cocta input must pass a diester alkaloid limit before extraction. High-performance liquid chromatography on a C18 column with UV detection at 235 nm or tandem mass spectrometry is used to separate aconitine, mesaconitine, and hypaconitine from their hydrolysates. The manufacturer applies an acceptance criterion expressed as total diester diterpene alkaloid equivalents, and the numerical limit is taken from the governing veterinary monograph or, where the monograph is absent, from a safety assessment based on the maximum intended dose in target species. The hydrolysis to benzoylaconine and aconine during decoction reduces toxicity but is not sufficient alone; chromatographic confirmation of residual diester alkaloids is required. For oral granules and powders, the API specification is paired with a processing record that includes decoction temperature, extraction time, and authentication of Aconitum species by macroscopic, microscopic, or DNA-based methods. This control differentiates the API from unstandardized Sini decoction powders that may contain variable levels of the parent alkaloids.

Published data for this exact three-herb extract configuration is limited; representative control targets are compiled from general botanical extract and nonsterile veterinary API practice. The table below lists typical release parameters for the oral powder. The injectable grade adds endotoxin and subvisible particulate controls after reconstitution.

For direct compression and capsule filling, the particle size distribution and moisture content of the API influence weight variation more than the ratio of the three herbs. Laser diffraction with dry dispersion at 1.5 bar is used to avoid particle swelling from the hygroscopic licorice fraction. A target D50 of 45–75 μm and D90 below 150 μm is maintained for oral powder blends; material above 180 μm is removed by conical milling with a 1.0 mm rasping screen. Hausner ratio is typically 1.25–1.40, indicating moderate flow. Without glidant, direct compression formulations may show weight variation above 2.0% at press speeds above 50 rpm on a 12-station rotary tablet press; therefore, fumed silica at 0.25–0.75% w/w or pre-mixing with 1–3% w/w of microcrystalline cellulose is used. The API is hygroscopic and should be pre-dried at 50°C in a vacuum oven when exposure to relative humidity above 60% has occurred before weighing.

Microbial Control and Endotoxin Budget for the Injectable Raw Material

The injectable presentation is controlled for bacterial endotoxin by USP 85 or EP 2.6.14, with the limit assigned from the highest intended dose per kilogram body weight. A conservative low-endotoxin API target is below 0.5 EU/mg; however, the final dosage form may require total endotoxin loading to be lower if large-volume parenteral administration is intended. The dried powder is not steam-sterilized in bulk because moist heat causes sintering, darkening, and marker loss. Instead, the manufacturer supplies the API with a validated bioburden limit, and the solution is reconstituted in water for injection at 40–60°C with high-shear mixing. After cooling to 25°C, the liquid is filtered through a 0.45 μm polypropylene prefilter and then a 0.22 μm PVDF or PES membrane. Nylon membranes should be avoided because polyphenolic constituents and licorice saponins can bind to unmodified polyamide surfaces and reduce marker recovery. The reconstituted solution should be inspected for subvisible particulates according to USP 788 or the equivalent veterinary pharmacopoeial method. Buffering capacity is low; citrate buffer at pH 5.0–6.5 is used to stabilize the solution against precipitation. Avoid pH below 4.0 because licorice saponins may precipitate; avoid pH above 7.5 because oxidation of polyphenols accelerates.

In medicated premix and granule manufacture, the primary processing risk is segregation of the concentrated API from large-particle carriers. In a 600 L ribbon blender charged to 70% of working volume, blending at 10–12 rpm for 15–20 min is used to distribute the API onto a matched carrier. The chopper is run for 60–90 s to reduce the number of undispersed API agglomerates. Premix uniformity is sampled with a powder thief at 10 points; release acceptance is 90–110% of target assay with a relative standard deviation not exceeding 5.0%. If the bulk density difference between API and carrier exceeds 0.25 g/cm³, the mixture may segregate during transfer through screw conveyors or bucket elevators; carrier particle size should be selected so that D50 values differ by no more than 20%. For granules, a wet binder solution of povidone K30 at 2–5% w/w is used in a high-shear granulator; drying is continued to a granule loss-on-drying below 3.0% at 50–60°C in a fluid-bed dryer to prevent caking in 25 kg HDPE bags.

When the API Is Spray-Dried, Bulk Density and Dispersibility Shift Formulation Behavior

Spray-dried Sini Decoction Powder Veterinary Grade API has a more spherical particle morphology and lower bulk density than vacuum-belt dried material. Typical bulk density after spray drying is 0.30–0.45 g/cm³, while vacuum-belt dried powder may reach 0.45–0.60 g/cm³. The lower density improves wetting in soluble oral powders and shortens reconstitution time, but it also increases dusting and cohesive arching in hoppers. Dry blending with denser carriers requires more aggressive shear or a stepwise geometric dilution to avoid floating API fines. For tablets, spray-dried API can produce compacts with adequate hardness at low compression force but may require additional lubricant to prevent picking and sticking on bi-layer tablet press turrets. If the powder is used in oral solutions, the material should be reconstituted in purified water at 40°C and then cooled; turbidity after 0.45 μm filtration is typically controlled below 20 NTU. If turbidity exceeds this threshold, clarification through diatomaceous earth or a 0.22 μm filter is applied before adding the remaining vehicle components.

Differences from Unstandardized Sini Crude Powders and Single-Marker Extracts

A crude comminuted mixture of the same three herbs retains starch, fiber, and plant cell debris, with marker content varying by growing region and batch. The veterinary API is extracted, filtered, concentrated, and dried to a uniform multi-constituent powder; therefore, it has lower acid-insoluble ash, lower microbial burden, and a defined alkaloid safety limit. It is not a premix. The material contains no calcium carbonate, corn starch, glucose, or mineral oil carriers. Compared with single-marker extracts or purified aconitine-type preparations, the API retains the decoction's licorice triterpene saponin and gingerol fractions, which influence solubility, palatability, and in vivo dissolution; this means that the active substance cannot be characterized by a single chemical reference standard alone. A chromatographic fingerprint with similarity of ≥0.95 against the validated reference extract is used as a batch-release identity method. Residual ethanol, when ethanol is used in extraction, is controlled by headspace gas chromatography at ≤0.5% w/w for non-injectable presentations.

For storage and handling, the powder should be held in double polyethylene liners within sealed HDPE drums at ≤25°C and ≤60% RH. Above 60% RH the API can absorb moisture and form lumps during coning; re-drying at 50°C in a vacuum oven before weighing is required. Avoid blending with anhydrous alkaline carriers or amine-based additives because the polyphenolic and saponin fractions may undergo oxidative browning and marker loss. Compatibility data with multivitamin-mineral premixes, choline chloride, and high-acid organic acid blends are limited; binary stability studies under 40°C/75% RH for 4 weeks are recommended before a new premix is released. The material is intended for further processing by veterinary license holders; it is not a finished feed supplement and should not be administered without reconciliation of the processed aconite alkaloid safety data for the target species.